{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:51:04Z","timestamp":1770349864856,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10147-023-02438-3","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T09:02:31Z","timestamp":1702026151000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients"],"prefix":"10.1007","volume":"29","author":[{"given":"Takanori","family":"Yoshimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-932X","authenticated-orcid":false,"given":"Tadayuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Ebisutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Mieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Sei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"2438_CR1","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","volume":"13","author":"DJ Uhlenhopp","year":"2020","unstructured":"Uhlenhopp DJ, Then EO, Sunkara T et al (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13:1010\u20131021","journal-title":"Clin J Gastroenterol"},{"key":"2438_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/j.gastro.2017.09.048","volume":"154","author":"DH Ilson","year":"2018","unstructured":"Ilson DH, van Hillegersberg R (2018) Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology 154:437\u2013451","journal-title":"Gastroenterology"},{"key":"2438_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof M et al (2021) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled cross trial. J Clin Oncol 39:1995\u20132004","journal-title":"J Clin Oncol"},{"key":"2438_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074\u20132084","journal-title":"N Engl J Med"},{"key":"2438_CR5","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/SLA.0000000000005533","volume":"278","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Kitagawa Y, Takemura R et al (2022) Real-world evaluation of the efficacy of neoadjuvant dcf over cf in esophageal squamous cell carcinoma: propensity score matched analysis from 85 authorized institutes for esophageal cancer in japan. Ann Surg 278:e35","journal-title":"Ann Surg"},{"key":"2438_CR6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705\u20131715","journal-title":"N Engl J Med"},{"key":"2438_CR7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/bjc.2016.350","volume":"115","author":"T Yokota","year":"2016","unstructured":"Yokota T, Kato K, Hamamoto Y et al (2016) Phase ii study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 115:1328\u20131334","journal-title":"Br J Cancer"},{"key":"2438_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of wbc growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"2438_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200262080-00012","volume":"62","author":"MP Curran","year":"2002","unstructured":"Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62:1207\u20131213 (discussion 1214\u20131205)","journal-title":"Drugs"},{"key":"2438_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ajco.13755","volume":"18","author":"O Maeda","year":"2022","unstructured":"Maeda O, Fukaya M, Koike M et al (2022) Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: a phase ii study. Asia Pac J Clin Oncol 18:578\u2013585","journal-title":"Asia Pac J Clin Oncol"},{"key":"2438_CR11","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1111\/cas.14218","volume":"110","author":"T Ishikawa","year":"2019","unstructured":"Ishikawa T, Yasuda T, Okayama T et al (2019) Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: a phase ii study. Cancer Sci 110:3754\u20133760","journal-title":"Cancer Sci"},{"key":"2438_CR12","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS et al (2015) American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563\u20132577","journal-title":"J Clin Oncol"},{"key":"2438_CR13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova R, Alsina M, Cervantes A et al (2022) Oesophageal cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:992\u20131004","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2438_CR14","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/383050","volume":"39","author":"J Klastersky","year":"2004","unstructured":"Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32-37","journal-title":"Clin Infect Dis"},{"key":"2438_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000329806","volume":"80","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Miyata H, Tanaka K et al (2011) Multicenter phase i\/ii study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80:307\u2013313","journal-title":"Oncology"},{"key":"2438_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/JTO.0b013e3181c1ffd5","volume":"5","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Arimura Y, Yamashita K et al (2010) Phase i\/ii study of docetaxel\/cisplatin\/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 5:122\u2013128","journal-title":"J Thorac Oncol"},{"key":"2438_CR17","first-page":"633","volume":"31","author":"Y Osaka","year":"2011","unstructured":"Osaka Y, Shinohara M, Hoshino S et al (2011) Phase ii study of combined chemotherapy with docetaxel, cddp and 5-fu for highly advanced esophageal cancer. Anticancer Res 31:633\u2013638","journal-title":"Anticancer Res"},{"key":"2438_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12032-014-0188-0","volume":"31","author":"V Noronha","year":"2014","unstructured":"Noronha V, Joshi A, Jandyal S et al (2014) High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (dcf) combination chemotherapy for locally advanced esophageal and junctional cancer. Med Oncol 31:188","journal-title":"Med Oncol"},{"key":"2438_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jamaoncol.2017.1114","volume":"3","author":"K Patel","year":"2017","unstructured":"Patel K, West HJ (2017) Febrile neutropenia. JAMA Oncol 3:1751","journal-title":"JAMA Oncol"},{"key":"2438_CR20","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"2438_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","volume":"3","author":"GH Lyman","year":"2005","unstructured":"Lyman GH (2005) Guidelines of the national comprehensive cancer network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3:557\u2013571","journal-title":"J Natl Compr Canc Netw"},{"key":"2438_CR22","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484","journal-title":"Ann Oncol"},{"key":"2438_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of eortc guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"2438_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage ii or stage iii\/iv breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"2438_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10147-018-1306-3","volume":"23","author":"M Kawahira","year":"2018","unstructured":"Kawahira M, Yokota T, Hamauchi S et al (2018) Primary prophylactic granulocyte colony-stimulating factor according to asco guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Int J Clin Oncol 23:1189\u20131195","journal-title":"Int J Clin Oncol"},{"key":"2438_CR26","first-page":"613","volume":"73","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Komori K, Aoki M et al (2018) Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. Pharmazie 73:613\u2013616","journal-title":"Pharmazie"},{"key":"2438_CR27","doi-asserted-by":"crossref","unstructured":"Ma X, Kang J, Li Y et al (2021) Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Support Palliat Care:bmjspcare-2020-002532","DOI":"10.1136\/bmjspcare-2020-002532"},{"key":"2438_CR28","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s00520-014-2270-8","volume":"22","author":"B Linot","year":"2014","unstructured":"Linot B, Augereau P, Breheret R et al (2014) Efficacy and safety of early g-csf administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (dcf protocol): a retrospective study. Support Care Cancer 22:2831\u20132837","journal-title":"Support Care Cancer"},{"key":"2438_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12032-022-01725-9","volume":"39","author":"Y Endo","year":"2022","unstructured":"Endo Y, Ishikawa T, Oka K et al (2022) Effect of concomitant use of g-csf and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model. Med Oncol 39:110","journal-title":"Med Oncol"},{"key":"2438_CR30","doi-asserted-by":"publisher","first-page":"djv368","DOI":"10.1093\/jnci\/djv368","volume":"108","author":"G Janoray","year":"2016","unstructured":"Janoray G, Pointreau Y, Garaud P et al (2016) Long-term results of a multicenter randomized phase iii trial of induction chemotherapy with cisplatin, 5-fluorouracil, +\/- docetaxel for larynx preservation. J Natl Cancer Inst 108:djv368. https:\/\/doi.org\/10.1093\/jnci\/djv368","journal-title":"J Natl Cancer Inst"},{"key":"2438_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/annonc\/mdn752","volume":"20","author":"MR Posner","year":"2009","unstructured":"Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in tax 324: Survival, surgery, and organ preservation. Ann Oncol 20:921\u2013927","journal-title":"Ann Oncol"},{"key":"2438_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.anl.2015.02.009","volume":"42","author":"H Cho","year":"2015","unstructured":"Cho H, Nishiike S, Yamamoto Y et al (2015) Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 42:396\u2013400","journal-title":"Auris Nasus Larynx"},{"key":"2438_CR33","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s00520-013-1873-9","volume":"21","author":"Y Takenaka","year":"2013","unstructured":"Takenaka Y, Cho H, Yamamoto M et al (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 21:2861\u20132868","journal-title":"Support Care Cancer"},{"key":"2438_CR34","first-page":"225","volume":"7","author":"SI Schuman","year":"2009","unstructured":"Schuman SI, Lambrou N, Robson K et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225\u2013228","journal-title":"J Support Oncol"},{"key":"2438_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ygyno.2008.10.025","volume":"112","author":"JM Whitworth","year":"2009","unstructured":"Whitworth JM, Matthews KS, Shipman KA et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601\u2013604","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02438-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:06:12Z","timestamp":1706151972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02438-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02438-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest. The authors have full control of all primary data and agree to allow the journal to review the data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}